Michael Harrington Buys 5,000 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) Director Michael Harrington acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was purchased at an average price of $21.82 per share, with a total value of $109,100.00. Following the completion of the transaction, the director directly owned 131,451 shares of the company’s stock, valued at $2,868,260.82. This trade represents a 3.95% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $23.64 on Friday. The company has a 50 day moving average of $24.56 and a 200 day moving average of $24.02. The stock has a market cap of $11.81 billion, a P/E ratio of -57.65, a P/E/G ratio of 1.35 and a beta of 1.67. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Get Elanco Animal Health alerts:

Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same period in the prior year, the company posted $0.26 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ELAN has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. UBS Group upped their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. KeyCorp raised their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Morgan Stanley lifted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 22nd. Finally, Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.09.

Read Our Latest Report on ELAN

Institutional Trading of Elanco Animal Health

A number of hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC increased its stake in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Elanco Animal Health during the second quarter worth about $38,000. Root Financial Partners LLC boosted its holdings in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new position in shares of Elanco Animal Health in the 4th quarter worth about $41,000. Finally, Torren Management LLC bought a new position in shares of Elanco Animal Health during the 4th quarter valued at about $46,000. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Featured Articles

• Five stocks we like better than Elanco Animal Health
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.